Stocks
Enanta Pharmaceuticals, Inc.ENTA
NASDAQHealthcareBiotechnology$12.70-5.29%
Focused on discovering and developing small molecule drugs for viral infections and liver diseases, this biotech firm is known for its hepatitis C treatments. Investors monitor its pipeline progress and partnerships with larger pharma companies.
Market Cap: $294.9M52W Range: $4.09 – $17.15
Congressional Interest in Enanta Pharmaceuticals, Inc. (ENTA)
2 members of Congress have disclosed 3 trades in Enanta Pharmaceuticals, Inc. (ENTA), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
1
Sells
2
Who in Congress Is Trading ENTA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-12 | Daniel Goldman | sell | $1K – $15K |
| 2015-05-27 | Thomas MacArthur | sell | $1K – $15K |